14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $5.34 $19.02 Tuesday, 7th May 2024 OTLK stock ended at $8.21. This is 3.41% less than the trading day before Monday, 6th May 2024. During the day the stock fluctuated 7.10% from a day low at $8.17 to a day high of $8.75.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Outlook Therapeutics Inc. prices

Date Open High Low Close Volume
Feb 26, 2024 $0.445 $0.455 $0.442 $0.448 553 323
Feb 23, 2024 $0.437 $0.460 $0.430 $0.439 1 967 414
Feb 22, 2024 $0.474 $0.474 $0.410 $0.429 1 332 637
Feb 21, 2024 $0.442 $0.446 $0.414 $0.418 1 051 548
Feb 20, 2024 $0.475 $0.489 $0.430 $0.434 2 125 864
Feb 16, 2024 $0.478 $0.485 $0.442 $0.452 1 830 278
Feb 15, 2024 $0.450 $0.500 $0.430 $0.485 5 107 954
Feb 14, 2024 $0.418 $0.440 $0.381 $0.420 1 200 479
Feb 13, 2024 $0.440 $0.440 $0.400 $0.400 906 875
Feb 12, 2024 $0.440 $0.450 $0.421 $0.437 1 375 223
Feb 09, 2024 $0.432 $0.456 $0.404 $0.414 1 075 330
Feb 08, 2024 $0.430 $0.460 $0.421 $0.449 2 876 097
Feb 07, 2024 $0.380 $0.430 $0.370 $0.421 2 420 359
Feb 06, 2024 $0.355 $0.385 $0.355 $0.385 872 183
Feb 05, 2024 $0.360 $0.388 $0.353 $0.356 825 389
Feb 02, 2024 $0.367 $0.370 $0.352 $0.364 828 595
Feb 01, 2024 $0.390 $0.400 $0.357 $0.363 1 493 964
Jan 31, 2024 $0.428 $0.428 $0.386 $0.386 1 782 728
Jan 30, 2024 $0.450 $0.450 $0.415 $0.415 1 077 559
Jan 29, 2024 $0.430 $0.450 $0.410 $0.446 1 377 810
Jan 26, 2024 $0.440 $0.450 $0.413 $0.432 1 486 396
Jan 25, 2024 $0.436 $0.452 $0.400 $0.435 4 315 837
Jan 24, 2024 $0.453 $0.460 $0.392 $0.400 3 637 830
Jan 23, 2024 $0.410 $0.456 $0.382 $0.444 27 596 110
Jan 22, 2024 $0.345 $0.350 $0.291 $0.340 1 400 902
Click to get the best stock tips daily for free!

About Outlook Therapeutics Inc.

Outlook Therapeutics. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice... OTLK Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT